Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: iron oxide red; iron oxide yellow; lactose; purified water; titanium dioxide; croscarmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; purified talc - colon cancer:,capecitabine is indicated for the adjuvant treatment of patients with duke?s stage c and highrisk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer:,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer:,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer:,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Kanada - Ingliż - Health Canada

taro pharmaceuticals inc - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

Kanada - Ingliż - Health Canada

taro pharmaceuticals inc - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents

Kanada - Ingliż - Health Canada

sivem pharmaceuticals ulc - capecitabine - tablet - 150mg - capecitabine 150mg

Kanada - Ingliż - Health Canada

sivem pharmaceuticals ulc - capecitabine - tablet - 500mg - capecitabine 500mg

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

apotex nz ltd - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - breast cancer capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. colon cancer capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high risk stage b colon cancer, either as monotherapy or in combination with oxaliplatin. colorectal cancer capecitabine is indicated for first-line treatment of patients with metastatic colorectal cancer. oesophagogastric cancer capecitabine is indicated for the first line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

rowex ltd - capecitabine - film-coated tablet - 150 milligram(s) - pyrimidine analogues; capecitabine

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

rowex ltd - capecitabine - film-coated tablet - 500 milligram(s) - pyrimidine analogues; capecitabine

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - capecitabine -